NVS - Genmab: An Attractive Biotechnology Platform Pick In March 2020
Today, we will see why Genmab (GMAB) is an attractive biotech pick in March 2020.
Company overview
Genmab is a dual-listed biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. The company was founded in 1999 in Copenhagen, Denmark. Genmab went public in Copenhagen and Frankfurt in 2000. In 2019, the company started trading on Nasdaq Copenhagen and Nasdaq Global Select Market exchanges in the U.S.
Genmab currently has three approved products in collaboration, Darzalex, Arzerra, and Tepezza. The company also has several proprietary clinical programs and